AU Stock MarketDetailed Quotes
TYP Tryptamine Therapeutics Ltd
- 0.033
- +0.001+3.13%
20min DelayMarket Closed Nov 1 16:00 AET
39.23MMarket Cap-362P/E (Static)
0.034High0.032Low5.67MVolume0.032Open0.032Pre Close186.24KTurnover0.03652wk High1.07%Turnover Ratio1.19BShares0.01752wk Low-0.038EPS TTM17.49MFloat Cap0.036Historical HighLossP/E (Static)529.89MShs Float0.017Historical Low-0.091EPS LYR6.25%Amplitude--Dividend TTM6.60P/B1Lot Size--Div YieldTTM
About Tryptamine Therapeutics Ltd Company
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Company Profile
SymbolTYP
Company NameTryptamine Therapeutics Ltd
Founded2013
MarketASX
Employees50
Fiscal Year Ends06-30
AddressC/o Bio101 Financial Advisory Pty Ltd 697 Burke Road, Suite 201
CityMelbourne
CountryAustralia
Zip Code3124
Phone+61 390920475
Share RegistryAUTOMIC REGISTRY SERVICES
Level 1, 45 Clarence Street, SYDNEY, NSW, AUSTRALIA, 2000
13 25 83
Company Executives
- Name
- Position
- Salary
- Ian Edward Dixon
- Chief Executive Officer,Managing Director
- --
- Mark Davies
- Non-Executive Chairman,Non-Executive Director
- --
- Clarke Barlow
- Non-Executive Director
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data